SCHEMBL6705585

SCHEMBL6705585

COC(=O)c1cccc(C(F)(F)F)c1-c1ccc(C(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
FABP4 P15090 1/20 0.43
PDK2 Q15119 3/20 0.42
CTSS P25774 3/20 0.41
APOB P04114 1/20 0.40
MTTP P55157 1/20 0.40
CTSK P43235 1/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
NOTUM Q6P988 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
PDK1 Q15118 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
SLC6A2 P23975 1/20 0.38
CFTR P13569 1/20 0.38
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706777 0.85 FABP4 (0.52) FABP4CTSSCTSKAKR1C3AKR1C2
SCHEMBL6705569 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EPDK2SLC6A4SLC6A3
SCHEMBL6699575 0.81 ALDH1A1 (0.48) ALDH1A1KDM4EFABP4SLC6A4SLC6A3
SCHEMBL6706499 0.81 ALDH1A1 (0.48) ALDH1A1KDM4EFABP4SLC6A4SLC6A3
SCHEMBL6696615 0.81 ALDH1A1 (0.48) ALDH1A1KDM4ESLC6A4SLC6A3HPGD
SCHEMBL6697433 0.80 HPGD (0.55) ALDH1A1KDM4EFABP4SLC6A4SLC6A3
SCHEMBL6704771 0.76 CFTR (0.45) KDM4EPDK2APOBMTTPSLC6A4
SCHEMBL20173743 0.75 CFTR (0.48) ALDH1A1KDM4EPDK2NOTUMHPGD
SCHEMBL6706507 0.74 CTSS (0.56) PDK2CTSSCTSKSLC6A4SLC6A3
SCHEMBL45490 0.73 LMNA (0.59) ALDH1A1KDM4EPDK2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors SMITHKLINE BEECHAM CORPORATION 2004-02-05 US disclosed
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 WO disclosed
EP-1289971-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2003-03-12 EP disclosed
WO-2001092241-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors APOB, APOL1, CETP ALDH1A1 4110/4885KDM4E 1519/4885FABP4 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.